This report is the latest in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that has been reporting data on HIV and AIDS in the WHO European Region and in the European Union and European Economic Area (EU/EEA) since 2007.
By 2021, 48 of 55 countries in Europe and Central Asia provided data on at least one stage of the continuum of HIV care (compared to 40 countries in 2018). A total of 47 countries were able to provide data for at least two consecutive stages of the continuum (compared to 45 in 2020) and 40 countries provided data on all four stages.
The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
For 2020, 28 EU/EEA countries reported 4 824 confirmed cases of Shiga toxin -producing Escherichia coli (STEC) infection. The overall notification rate was 1.6 cases per 100 000 population. The highest notification rates were reported in Ireland, Malta, Denmark, and Norway. The EU/EEA notification rate decreased notably in 2020 compared with 2016-2019 due to the COVID-19 pandemic.